Gamida Cell Ltd. $50 Million Initial Public Offering

Meitar Liquornik Geva Leshem Tal, Ramat Gan, Cooley LLP and Davis Polk advised on the transaction

Based in Jerusalem, Israel, Gamida Cell is a clinical stage biopharmaceutical company that leverages its proprietary nicotinamide-, or NAM-, based cell expansion technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases.

BMO Capital Markets, RBC Capital Markets acted as Joint Book-Running Managers and Needham & Company, Oppenheimer & Co. acted as Co-Lead Managers on the offering.

Cooley advised Gamida Cell Ltd. with a team including Div Gupta, Daniel I. Goldberg, Josh Kaufman, Dayne Brown and Adam Alperowicz.

Davis Polk advised the representatives of the underwriters with a team including Michael Kaplan and Derek Dostal and associates Joseph S. Payne and Sana Bargach. The tax team included partner Rachel D. Kleinberg and associate Gil Savir. The intellectual property and technology team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Adam Alperowicz – Cooley LLP; Dayne Brown – Cooley LLP; Daniel Goldberger – Cooley LLP; Div Gupta – Cooley LLP; Josh Kaufman – Cooley LLP; Sana Bargach – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Derek Dostal – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Michael Kaplan – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Joseph Payne – Davis Polk & Wardwell; Gil Savir – Davis Polk & Wardwell;

Law Firms: Cooley LLP; Davis Polk & Wardwell;

Clients: BMO Capital Markets; Gamida Cell Ltd; Needham & Co.; Oppenheimer & Co; RBC Capital Markets;

Author: Ambrogio Visconti